Silence Therapeutics (Silence Therapeutics) EV-to-EBIT : -15.36 (As of May. 02, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Silence Therapeutics EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Silence Therapeutics's Enterprise Value is $930.32 Mil. Silence Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-60.58 Mil. Therefore, Silence Therapeutics's EV-to-EBIT for today is -15.36.

The historical rank and industry rank for Silence Therapeutics's EV-to-EBIT or its related term are showing as below:

SLN' s EV-to-EBIT Range Over the Past 10 Years
Min: -43.16 Med: -6.35 Max: -0.04
Current: -15.36

During the past 13 years, the highest EV-to-EBIT of Silence Therapeutics was -0.04. The lowest was -43.16. And the median was -6.35.

SLN's EV-to-EBIT is ranked worse than
100% of 438 companies
in the Biotechnology industry
Industry Median: 8.725 vs SLN: -15.36

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Silence Therapeutics's Enterprise Value for the quarter that ended in Dec. 2023 was $620.07 Mil. Silence Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-60.58 Mil. Silence Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -9.77%.

Silence Therapeutics EV-to-EBIT Historical Data

The historical data trend for Silence Therapeutics's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Silence Therapeutics EV-to-EBIT Chart

Silence Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

Get a 7-Day Free Trial

-10.34

-10.97

-8.93

-4.58

-1.73

Silence Therapeutics Quarterly Data
	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial															-4.58	-3.25	-0.59	-0.16	-1.73

Competitive Comparison of Silence Therapeutics's EV-to-EBIT

For the Biotechnology subindustry, Silence Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Silence Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Silence Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Silence Therapeutics's EV-to-EBIT falls into.

Silence Therapeutics EV-to-EBIT Calculation

Silence Therapeutics's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	930.317	/	-60.581
	=	-15.36

Silence Therapeutics's current Enterprise Value is $930.32 Mil.
Silence Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-60.58 Mil.

Silence Therapeutics (NAS:SLN) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Silence Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=	-60.581	/	620.074709
	=	-9.77 %

Silence Therapeutics's Enterprise Value for the quarter that ended in Dec. 2023 was $620.07 Mil.
Silence Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-60.58 Mil.

Silence Therapeutics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Silence Therapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Silence Therapeutics (Silence Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Silence Therapeutics PLC (NAS:SLN) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

SLNCF:USA XRP2:Germany

Address

72 Hammersmith Road, London, GBR, W14 8TH

Website

https://www.silence-therapeutics.com

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid. its pipeline products are; SLN360 therapy designed to temporarily block a specific gene's message that would otherwise trigger an unwanted effect. By silencing the LPA gene, the levels of Lp(a) are lowered, which in turn is expected to lower the risk of heart diseases, heart attacks, and strokes, and SLN124 therapy aims to temporarily silence TMPRSS6, a gene that prevents the liver from producing a particular hormone that controls iron levels in the body hepcidin. As hepcidin increases, iron levels in the blood are expected to decrease, which may increase the production of healthy red blood cells, thereby reducing anemia.